Activity Against Drug-Resistant Pathogens is One of the Leading Attributes Influencing Physicians' Antibiotic Selection for the Treatment of Inpatient Community-Acquired Pneumonia
Posted on: Tuesday, 24 February 2009, 07:00 CST
Future Therapies Modeled After Johnson & Johnson/Basilea's or Forest/Novexel's Drug Could Be Used As First-Line Therapies, According to a New Report from AMR and Decision Resources
The new report entitled Hospital Anti-Infectives Insight Series: Community-Acquired Pneumonia also finds that future therapies modeled after Johnson & Johnson/Basilea's ceftobiprole or Forest/Novexel's ceftaroline could be used as empiric first-line therapies for very severe cases of community-acquired pneumonia requiring admission to the ICU or mechanical ventilation.
"Ceftobiprole and ceftaroline couple broad-spectrum cephalosporin activity with targeted activity against MRSA, offering physicians enhanced pathogen coverage for empiric treatment of community-acquired pneumonia in the hospital setting," stated
About Hospital Anti-Infectives Insight Series
AMR and Decision Resources' new Hospital Anti-Infectives Insight Series analyzes hospital antibiotic prescribing patterns using AMR's comprehensive and highly detailed clinical data in conjunction with Decision Resources' disease area knowledge, primary research and extensive understanding of emerging therapies and forecasts. These reports examine the reasons behind physicians' product preferences, factors driving hospital antibiotic prescribing patterns and receptivity to emerging antibiotics.
About AMR
AMR (www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.
About Decision Resources
Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Natalia Morales Elizabeth Marshall Decision Resources Decision Resources, Inc. 781-296-2691 781-296-2563 nmorales@dresources.com emarshall@dresources.comSOURCE Decision Resources
Source: PR Newswire
Related Articles
- Despite Generic Erosion of Key Brands, the Hospital-Acquired Gram Negative Infections Drug Market Will Increase by $1 Billion from 2008 to 2018
- FDA Approves New Indication for Wyeth's TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia
- AdvanDx's PNA FISH(TM) Test Shown to Reduce Mortality By 42% for Patients With Hospital-Acquired Enterococcus Faecium Bloodstream Infections
- FirstDoNoHarm.Com to Help Healthcare Practitioners and Executives Reduce the Human and Financial Toll Exacted By Hospital-Acquired Conditions (HACs)
- Novel Glycopeptides and Cephalosporins Will Drive the Hospital-Acquired Infections Drug Market Through 2017
- Basilea Announces Positive Top-Line Data From Phase III Study of Ceftobiprole in Hospital-Acquired Pneumonia
- Nektar Threraputics Announces Phase 2a Clinical Results Regarding the Use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative Hospital-Acquired Pneumonia Presented at the Annual American Thoracic Society International Conference
- Impact of Clinical Guidelines in the Management of Severe Hospital- Acquired Pneumonia*
- Poll Shows Hospitals Reducing Serious Hospital-Acquired Infection
- Guidelines for the Management of Adults With Hospital-Acquired, Ventilator-Associated, and Healthcare-Associated Pneumonia
 |
 |
User Comments (0)
RSS Feeds